Log in to search using one of your social media accounts:

This page shows you the latest news items in this category.

Milo Biotechnology receives orphan drug designation for AAV1-FS344 to treat inclusion body myositis
Milo Biotechnology has secured Orphan Drug designation for its AAV1-FS344 from the Federal Drug Administration ’s (FDA) Office of Orphan Products Development for treatment of inclusion body myositis. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 6, 2016 Category: Pharmaceuticals Source Type: news

New drug shows promise against muscle wasting disease
A new drug to treat the muscle wasting disease inclusion body myositis reverses key symptoms in mice and is safe and well-tolerated in patients, finds a new study led by the Medical Research Council Centre for Neuromuscular Diseases at University College London. (Source: Medical Research Council General News)
Source: Medical Research Council General News - March 24, 2016 Category: Research Source Type: news

Misdiagnosis of Inclusion Body MyositisMisdiagnosis of Inclusion Body Myositis
As these cases demonstrate, correct diagnosis of sporadic inclusion body myositis is challenging, often resulting in mis-diagnosis, inappropriate therapies, and unnecessary fears. Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 23, 2015 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

New compound BYM338 could reverse loss of muscle mass in cancer and other diseases
A new antibody could dramatically boost strength and muscle mass in patients with cancer, chronic obstructive pulmonary disease (COPD), sporadic inclusion body myositis, and in elderly patients with sarcopenia according to research published ahead of print in the journal Molecular and Cellular Biology."Age-related loss of muscle mass is a major contributing factor to falls, broken bones, and the loss of mobility," says co-corresponding author David Glass of Novartis, Cambridge, MA, one of the compound's developers, along with first author Estelle Trifilieff, also of Novartis. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 31, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

New compound could reverse loss of muscle mass in cancer and other diseases
(American Society for Microbiology) A new antibody could dramatically boost strength and muscle mass in patients with cancer, chronic obstructive pulmonary disease, sporadic inclusion body myositis, and in elderly patients with sarcopenia according to research published ahead of print in the journal Molecular and Cellular Biology. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - December 19, 2013 Category: Global & Universal Source Type: news

Frequency and circumstances of falls in people with inclusion body myositis: A questionnaire survey to explore falls management and physiotherapy provision - Hiscock A, Dewar L, Parton M, Machado P, Hanna M, Ramdharry G.
OBJECTIVES: To survey the incidence and circumstances of falls for people with inclusion body myositis (IBM) in the UK, and to investigate the provision of physiotherapy and falls management. DESIGN: Postal questionnaire survey. SETTING: Participants compl... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - December 17, 2013 Category: Global & Universal Tags: Falls Source Type: news

FDA breakthrough therapy designation for bimagrumab
Novartis announced today that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to BYM338 for sporadic inclusion body myositis (sIBM). You must sign in to continue reading this article Hide related content:  Show related content read more (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 22, 2013 Category: Drugs & Pharmacology Authors: mz_loader Tags: *** Editor's Pick Latest News Source Type: news

FDA breakthrough therapy designation for bimagrumab
Novartis announced today that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to BYM338 for sporadic inclusion body myositis (sIBM). (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 21, 2013 Category: Drugs & Pharmacology Source Type: news

Novartis muscle wasting drug gets 'breakthrough' status
ZURICH (Reuters) - Novartis said on Thursday U.S. regulators have granted breakthrough therapy status for its investigational compound bimagrumab for the potential treatment of patients with sporadic inclusion body myositis (sIBM). (Source: Reuters: Health)
Source: Reuters: Health - August 20, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Ultragenyx reports positive interim data from Phase II study of oral sialic acid tablet
Clinical-stage biotechnology company Ultragenyx Pharmaceutical has reported positive interim data from Phase II study of an oral sialic acid extended-release (SA-ER) tablet, UX001, in hereditary inclusion body myopathy (HIBM). (Source: Drug Development Technology)
Source: Drug Development Technology - July 5, 2013 Category: Pharmaceuticals Source Type: news

Single Mutations In VCP Gene Implicated In A Number Of Neurodegenerative Diseases
This study shows that these mutations disrupt energy production in cells shedding new light on the role of VCP in these multiple disorders... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 18, 2013 Category: Consumer Health News Tags: Alzheimer's / Dementia Source Type: news

Mutations in VCP gene implicated in a number of neurodegenerative diseases
(University College London) New research, published in Neuron, gives insight into how single mutations in the VCP gene cause a range of neurological conditions including a form of dementia called Inclusion Body Myopathy, Paget's Disease of the Bone and Frontotemporal Dementia, and the motor neuron disease Amyotrophic Lateral Sclerosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 14, 2013 Category: Global & Universal Source Type: news